IRWD Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

55.43M

-38.78%

0.040

+100%

56.60M

+37.57%

0.035

-125%

99.00M

+16.14%

0.200

+42.86%

Estimates Revision

The market is revising No Change the revenue expectations for Ironwood Pharmaceuticals, Inc. (IRWD) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 129.38%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Up

+129.38%

In Past 3 Month

Valuation Metrics

The current forward P/E ratio for Ironwood Pharmaceuticals Inc (IRWD.O) is 6.83, compared to its 5-year average forward P/E of 14.28. For a more detailed relative valuation and DCF analysis to assess Ironwood Pharmaceuticals Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

14.28

Current PE

6.83

Overvalued PE

35.47

Undervalued PE

-6.91

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

9.86

Current EV/EBITDA

5.06

Overvalued EV/EBITDA

16.29

Undervalued EV/EBITDA

3.42

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

3.28

Current PS

2.02

Overvalued PS

4.79

Undervalued PS

1.76

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

IRWD News & Events

Events Timeline

No data

News

4.0

01-05Benzinga

Trump Announces U.S. Oil Companies to Invest Billions in Venezuela Post-Maduro

4.5

01-02Yahoo Finance

Health Care Stocks Mixed as NYSE Health Care Index Edges Up

8.5

01-02Benzinga

Intelligent Bio Solutions Plans $10 Million Private Placement, Shares Plunge 19.7%

People Also Watch

Frequently Asked Questions

What is Ironwood Pharmaceuticals Inc (IRWD) stock price today?

The current price of IRWD is 4.06 USD — it has increased 2.01 % in the last trading day.

What is Ironwood Pharmaceuticals Inc (IRWD)'s business?

Ironwood Pharmaceuticals, Inc. is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI), and rare diseases. It is focused on the development and commercialization of GI product opportunities in areas of significant unmet need. LINZESS (linaclotide), its commercial product, is indicated for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C), or chronic idiopathic constipation (CIC), and for pediatric patients ages 6-17 years-old suffering from functional constipation (FC). Linaclotide is available under the trademarked name CONSTELLA to adult men and women suffering from IBS-C or CIC and pediatric patients. The Company is also engaged in advancing apraglutide, a synthetic long-acting peptide analog of glucagon-like peptide-2 (GLP-2), for short bowel syndrome (SBS), patients who are dependent on parenteral support.

What is the price predicton of IRWD Stock?

Wall Street analysts forecast IRWD stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for IRWD is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Ironwood Pharmaceuticals Inc (IRWD)'s revenue for the last quarter?

Ironwood Pharmaceuticals Inc revenue for the last quarter amounts to 122.06M USD, increased 33.26 % YoY.

What is Ironwood Pharmaceuticals Inc (IRWD)'s earnings per share (EPS) for the last quarter?

Ironwood Pharmaceuticals Inc. EPS for the last quarter amounts to 0.23 USD, increased 1050.00 % YoY.

What changes have occurred in the market's expectations for Ironwood Pharmaceuticals Inc (IRWD)'s fundamentals?

How many employees does Ironwood Pharmaceuticals Inc (IRWD). have?

Ironwood Pharmaceuticals Inc (IRWD) has 253 emplpoyees as of January 10 2026.

What is Ironwood Pharmaceuticals Inc (IRWD) market cap?

Today IRWD has the market capitalization of 660.48M USD.